Drugs / Rifasutenizol
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06551623 | Aug → Oct 2024 | Helicobacter pylori infectious disease | TenNor Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT06137573 | Jul → Sep 2022 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06081712 | Oct 2020 → Jul 2021 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06081699 | May → Sep 2019 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06076681 | Sep 2021 → Jan 2022 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06076694 | Jun → Sep 2022 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05857163 | May → Dec 2023 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rifasutenizol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05857163 ↗ |
| Known as | TNP-2198 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06081712 ↗ |
| Modality | Small molecule | — CHEMBL5172403 ↗ |
| Route | Oral | “400 mg, BID, taken orally within half an hour after breakfast and dinner.” NCT05857163 ↗ |